Onvansertib Triplet Improves Efficacy in First-Line RAS-Mutated mCRC
In the realm of medical advancement, a new treatment, Onvansertib Triplet, has shown promising enhancement in efficacy against RAS-mutated mCRC.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
In a significant turn, the FDA has issued a partial hold on the Lorigerlimab trial aimed at tackling gynecologic cancers.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
Progress has also been seen in the domain of melanoma treatment, particularly in the management of toxicities induced by immune-checkpoint inhibitors.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
The FDA has also granted a swift approval procedure, known as Fast Track Designation, for SRN-101, a novel immuno-gene therapy former for the treatment of major recurrent glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
Further, a new molecule has reported promising results in the initial phases of multiple myeloma treatment.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
In terms of therapeutic techniques for oropharyngeal cancer, a comparative study has been conducted to evaluate the quality of life outcomes when treated with Protons versus Photons.
